Forbion, one of the leading European life science venture capital firms, today announced that it led the $19 million Series B financing of Escalier Biosciences BV, a privately held biopharmaceutical company based in Nijmegen, The Netherlands. Escalier Biosciences is developing both oral and topical ROR?t drug candidates for psoriasis and other autoimmune diseases.
Dova Pharmaceuticals, Inc. (DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, entered into an agreement through its wholly owned subsidiary, AkaRx, Inc., granting Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) (SHA:600196) (HKG:02196), the exclusive development and distribution rights of avatrombopag in mainland China and Hong Kong.
Tuesday, March 20th, 2018, Insilico Medicine, a Baltimore-based artificial intelligence company specializing in drug discovery, biomarker development and aging research announced the launch of Insilico Taiwan, a subsidiary focusing on the development and validation of generative adversarial networks(GANs) and reinforcement learning for medicinal chemistry applications.
UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, announced the closing of a $55 million Series C financing.
Singapore-based DocDoc, an Asian patient empowerment company, announced on March 19 that it has raised US$5.45 million (RM21.33 million) in their Series B round of funding.
In 2017, GlaxoSmithKline ended its partnership with Ionis Pharmaceuticals, Inc. to develop and market inotersen and a follow-up drug for rare diseases. After reviewing its options, Ionis has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion. What makes this deal a bit unusual is that Akcea is a subsidiary of Ionis.
First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
A new study out of Vanderbilt University Medical Center found genetic data in electronic health records can be used to spot undiagnosed diseases.
Using electrochemical stimulation and robot-assisted rehabilitation techniques, researchers restore walking ability in a paraplegic rat. The study reports reorganization of neural branching in the reticular formation leads to new connections and is key to motor skill recovery.
NnBu Holdings has developed a blockchain medical device to help deliver healthy outcomes for babies born by C-section.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.